Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting positions in Moderna.

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BRSE:0QF) from Buy to Neutral. There are 1,448 funds or institutions reporting positions in Moderna.

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares MRNA fell 2% in ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...